A Multicenter, Randomized, Controlled Study Comparing the Efficacy and Safety of 48 Weeks of 40kD Branched Pegylated Interferon Alfa-2a (PEG-IFN, RO 25-8310) Versus 96 Weeks of PEG-IFN, Alone or in Combination With 100 mg Lamivudine for 48 Weeks in Patients With HBeAg-Negative Chronic Hepatitis B

Trial Profile

A Multicenter, Randomized, Controlled Study Comparing the Efficacy and Safety of 48 Weeks of 40kD Branched Pegylated Interferon Alfa-2a (PEG-IFN, RO 25-8310) Versus 96 Weeks of PEG-IFN, Alone or in Combination With 100 mg Lamivudine for 48 Weeks in Patients With HBeAg-Negative Chronic Hepatitis B

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Lamivudine
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Acronyms PegBeLiver
  • Sponsors Roche
  • Most Recent Events

    • 16 Apr 2010 Actual patient number (129) added as reported by ClinicalTrials.gov.
    • 16 Apr 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
    • 31 Mar 2010 Planned end date (Jun 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top